Nebibeta (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebibeta, is a beta‑blocker presented as an oral tablet for oral use. It lowers blood pressure in adults with hypertension.

GNH USA supplies Nebibeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of cardiovascular conditions.

Hypertension: reduces systolic and diastolic blood pressure in patients with high blood pressure. Heart failure with reduced ejection fraction: improves cardiac output and symptoms in eligible patients. High‑risk cardiovascular patients: helps lower the risk of cardiovascular events when combined with standard therapy.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Fatigue or tiredness - Headache - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Nausea or abdominal discomfort - Nasal congestion

Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute bronchospasm in patients with asthma - Hepatic injury or elevated liver enzymes - Allergic reactions such as rash or angioedema - Hypotension leading to syncope

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential risks. - Monitor blood pressure: check regularly to ensure therapeutic effect. - Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. - Caution in asthma or COPD: may precipitate bronchospasm. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Review concomitant medications: assess for interactions that may affect safety. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other beta‑blockers: may cause excessive bradycardia. - Combined with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - Use with potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Concomitant ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: can increase risk of electrolyte disturbances and orthostatic hypotension. - Antidiabetic agents: nebivolol may mask hypoglycemia symptoms. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (SSRIs): monitor for additive bradycardia.